TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04212039

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution
Description: 0.5 ml/kg saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.5 ml/kg %0.25 bupivacaine
Study: NCT01004172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herceptin
Study: NCT04518774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-vivo expanded allogeneic γδT cells
Description: Cells will be extracted from a healthy donor by apheresis, followed by ex-vivo expansion and activation. The ex-vivo expanded γδT cells from donors will be adoptively transfused.
Study: NCT01922349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Medium dose (Multiple dosing)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Multiple dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose (Multiple dosing)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: High dose (Single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Medium dose (Single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: Low dose (Single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: High dose (Multiple dosing)
Study: NCT00322478

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Automated informatics driven education and social networking
Description: The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Blood Glucose Notifications to Remote Caregivers
Description: When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Frequency of Pattern Management
Description: The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
Study: NCT04572100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transoral Robotic Surgery (TORS) or Radiotherapy
Description: Participants assigned to this group will receive transoral robotic surgery (TORs) or radiotherapy. Radiotherapy is given once a day for 5 weeks. A percentage of subjects who undergo surgery may need further radiotherapy with or without chemotherapy based on the results of the surgery. TORs is surgery in which a robot with arms is used to remove cancer from hard-to-reach areas of the mouth and throat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and Low-Dose Radiotherapy
Description: Participants assigned to this group will receive 5 weeks of chemotherapy combined with low- dose radiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and High-Dose Radiotherapy
Description: Participants assigned to this group will receive 7 weeks of chemotherapy combined with high- dose radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: This drug will be combined with carboplatin during induction therapy for 9 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: This drug will be combined with paclitaxel during induction therapy for 9 weeks.
Study: NCT04637997

Intervention type: DEVICE
Group type: OTHER
Intervention: compression stockings class I
Description: Daily wearing of compression stockings class I for four weeks on the affected extremity.

Intervention type: DEVICE
Group type: OTHER
Intervention: compression stockings class I
Description: Daily wearing of compression stockings class I for four weeks on the affected extremity.

Intervention type: DEVICE
Group type: OTHER
Intervention: compression stockings class II
Description: Daily wearing of compression stockings class II for four weeks on the affected extremity.

Intervention type: DEVICE
Group type: OTHER
Intervention: compression stockings class II
Description: Daily wearing of compression stockings class II for four weeks on the affected extremity.
Study: NCT02699164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal stabilization exercise
Description: spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal stabilization exercise
Description: spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
Study: NCT01693952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood draw
Study: NCT00375661

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: interferon-alfa-2b and ribavirin
Description: Interferon, pnce per week plus daily ribavirin
Study: NCT03271697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Membranaceus
Description: This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as a comparator comparing with AM group
Study: NCT00125918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study: NCT03434990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation/myofascial release
Description: The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal manipulation
Description: The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
Study: NCT02240459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fesoterodine 4mg
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxybutynin
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning
Study: NCT00125918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
Study: NCT02240459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fesoterodine 8mg
Description: 2, 4mg fesoterodine capsules taken together in the morning
Study: NCT00125918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet taken by mouth once a day for 16 weeks
Study: NCT00446043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide
Description: Adapalene 0.1 percent (%) \[weight by weight (W/W)\] and benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening.
Study: NCT04155736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Renew
Description: Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Renew
Description: Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
Study: NCT04289051

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HYDRAL Oral Rinse
Description: Application 4 times a day for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYDRAL Oral Rinse
Description: Application 4 times a day for two weeks
Study: NCT04005872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride
Description: Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
Study: NCT01649219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT01993199

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep biopsy via ESD technique
Study: NCT01502553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison Test to Yuyue Medical BP Meter, YYBP-212
Description: DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
Study: NCT04289051

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HYDRAL Oral Rinse
Description: Application 4 times a day for two weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOTENE® Oral Rinse
Description: Application 4 times a day for two weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOTENE® Oral Rinse
Description: Application 4 times a day for two weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BIOTENE® Oral Rinse
Description: Application 4 times a day for two weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Rinse
Description: Application 4 times a day for two weeks
Study: NCT01391611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg; PO
Study: NCT01586325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 30 mg
Description: JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 90 mg
Description: JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 200 mg
Description: JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo administered once daily as monotherapy for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo administered once daily as monotherapy for 5 days.
Study: NCT04289051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Oral Rinse
Description: Application 4 times a day for two weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Rinse
Description: Application 4 times a day for two weeks
Study: NCT02018939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic profiling
Description: Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic profiling
Description: Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic profiling
Description: Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
Study: NCT01901341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945
Study: NCT01586325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo administered once daily as monotherapy for 5 days.
Study: NCT02423408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-201
Description: TNX-201 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT00486044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg tablet each night for one month, then 80 mg for 8 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablet each night for 9 months
Study: NCT04989673

Intervention type: OTHER
Intervention: Biological sampling and collection (serum)
Description: Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups

Intervention type: OTHER
Intervention: Biological sampling and collection (serum)
Description: Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups

Intervention type: OTHER
Intervention: Biological sampling and collection (serum)
Description: Detection of the dengue virus during the next scheduled biological assessment as part of normal pregnancy monitoring (additional tube of blood) among women from GNES and GNEF groups

Intervention type: OTHER
Intervention: Biological sampling and collection (placenta)
Description: Detection of dengue virus in the placenta of GE patients (additional tube of placenta)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on the patient's socio-economic conditions (10-minute interview with the Clinical Research Associate, CRA).

Intervention type: OTHER
Intervention: Data collection
Description: Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).

Intervention type: OTHER
Intervention: Data collection
Description: Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).

Intervention type: OTHER
Intervention: Data collection
Description: Case Report Form will be completed by a Clinical Research Associate (CRA) from the medical file of the patient concerned and of her child at the 3 visits carried out (Pre inclusion V0 or Inclusion V1, Childbirth V2 and Maternity leave V3).
Study: NCT02422654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat
Description: Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion
Study: NCT01183923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli Sprouts
Description: Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli Sprouts
Description: Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfalfa Sprouts
Description: Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.